Person: ÇAVUN, SİNAN
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
ÇAVUN
First Name
SİNAN
Name
4 results
Search Results
Now showing 1 - 4 of 4
Publication Central injection of CDP-choline suppresses serum ghrelin levels while increasing serum leptin levels in rats(Elsevier, 2015-07-06) Kıyıcı, Sinem; Başaran, Nesrin Filiz; Çavun, Sinan; Savcı, Vahide; Kıyıcı, Sinem; Başaran, Nesrin Filiz; ÇAVUN, SİNAN; SAVCI, VAHİDE; Tıp Fakültesi; Farmakoloji Ana Bilim Dalı; 0000-0002-0076-6554; AAC-9702-2019; KHD-9454-2024; FGL-7924-2022; GBK-8383-2022In this study we aimed to test central administration of CDP-choline on serum ghrelin, leptin, glucose and corticosterone levels in rats.lntracerebroventricular (i.c.v.) 0.5,1.0 and 2.0 mu mol CDP-choline and saline were administered to male Wistar-Albino rats. For the measurement of serum leptin and ghrelin levels, blood samples were obtained baseline and at 5, 15, 30, 60 and 120 min following i.c.v., CDP-choline injection. Equimolar doses of i.c.v. choline (1.0 mu mol) and cytidine (1.0 mu mol) were administered and measurements were repeated throughout the second round of the experiment. Atropine (10 mu g) and mecamylamine (50 mu g) were injected intracerebroventricularly prior to CDP-choline and measurements repeated in the third round of the experiment. After 1 mu mol CDP-choline injection, serum ghrelin levels were suppressed significantly at 60 min (P=0.025), whereas serum leptin levels were increased at 60 and 120 min (P=0.012 and P=0.017 respectively). CDP-choline injections also induced a close- and time-dependent increase in serum glucose and corticosterone levels. The effect of choline on serum leptin and ghrelin levels was similar with CDPcholine while no effect was seen with cytidine. Suppression of serum ghrelin levels was eliminated through mecamylamine pretreatment while a rise in leptin was prevented by both atropine and mecamylamine pretreatments.In conclusion; centrally injected CDP-choline suppressed serum ghrelin levels while increasing serum leptin levels. The observed effects following receptor antagonist treatment suggest that nicotinic receptors play a role in suppression of serum ghrelin levels,whereas nicotinic and muscarinic receptors both play a part in the increase of serum leptin levels. (C) 2015 Elsevier B.V. All rights reserved.Publication Evaluation of the relationship between proinflammatory cytokine levels and clinical findings of fibromyalgia syndrome(Shiraz Inst Cancer Res, 2021-01-01) Ellergezen, Pınar; Alp, Alev; Çavun, Sinan; ELLERGEZEN, PINAR; ALP, ALEV; ÇAVUN, SİNAN; Tıp Fakültesi; Fiziksel Tıp ve Rehabilitasyon Ana Bilim Dalı; AAC-9702-2019; ICM-4005-2023; EKZ-2544-2022Background: Immune system has an important effect on pain related disorders such as fibromyalgia syndrome (FMS). There is no specific laboratory technique for the diagnosis of FMS, but measuring serum proinflammatory cytokines may help. Objective: The purpose of our study was to determine the serum levels of immune mediators and their relationship with FMS symptoms. Methods: 25 healthy individuals and 29 FMS patients receiving pregabalin 150 mg/day for a minimum of 3 months were included in this study. FMS patients were diagnosed according to diagnostic criteria of the American College of Rheumatology (ACR 2010). Widespread pain index (WSI), fatigue, waking unrefreshed, cognitive symptoms, somatic symptoms, and Fibromyalgia Impact Questionnaire (FIQ) scores were evaluated in patients with FMS. Serum levels of proinflammatory cytokines (IL-2, IL-6, IL 12, IL-17, IFN-gamma, TNF-alpha) were assessed using enzyme-linked immunosorbent assay (ELISA). Results: Proinflammatory cytokine levels were higher in the control group than patients with FMS (P<0.05). A positive correlation was found between age and WSI (P=0.037). In addition, a significant positive relationship was determined between IL-17 level and waking unrefreshed (P=0.049). There was no significant relationship between other cytokines and clinical findings. Conclusion: Lower proinflammatory cytokine levels identified in FMS patients may be related to pregabalin treatment, and there may be an impairment in the inflammatory response. On the contrary, IL-17 showed positive correlation with waking unrefreshed.Publication Pregabalin inhibits proinflammatory cytokine release in patients with fibromyalgia syndrome(Turkish League Against Rheumatism, 2023-06-01) Ellergezen, Pınar; ALP, ALEV; ELLERGEZEN, PINAR; ÇAVUN, SİNAN; Çavun, Sinan; Çelebi, Melih; ÇELEBİ, MELİH; Macunluoğlu, Aslı Ceren; Tıp Fakültesi; Farmakoloji Ana Bilim Dalı; 0000-0002-6802-5998; AAC-9702-2019; JFJ-7690-2023Objectives: The main goal of the study was to investigate how pregabalin (PGB) affects proinflammatory cytokine release in patients with fibromyalgia syndrome (FMS).Patients and methods: This experimental research study was conducted with 85 female participants (mean age: 49.6 & PLUSMN;10.1 years; range, 30 to 73 years) between April 2020 and November 2020. Of the participants, 30 were FMS patients using PGB 150 mg/day for at least three months, 30 were FMS patients not using PGB, and 25 were healthy individuals. The detection of FMS was carried out according to the 2010 American College of Rheumatology diagnostic criteria. Levels of proinflammatory cytokines (interleukin [IL]-2, IL-6, IL-12, IL-17, interferon-gamma, and tumor necrosis factor-alpha) were measured by enzyme-linked immunosorbent assay.Results: Serum concentrations of proinflammatory cytokines were remarkably decreased in FMS patients using PGB (p<0.001) and were higher in patients with FMS not using PGB than in healthy subjects (p<0.001). The highest values of proinflammatory cytokines were found in the group of FMS patients not using PGB (p<0.001).Conclusion:These results indicate that PGB inhibits the release of proinflammatory cytokines, suggesting that it can be used as an anti-inflammatory agent in inflammatory cases.Publication Fibromiyalji sendromunda sistemik immün-inflamasyon indeksi ve hematolojik laboratuvar bulgularına genel bakış(Bursa Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2024-05-21) Ellergezen, Pınar; Alp, Alev; Çavun, Sinan; Çeçen, Gülce Sevdar; ELLERGEZEN, PINAR; ALP, ALEV; ÇAVUN, SİNAN; SEVDAR ÇEÇEN, GÜLCEBu çalışmada fibromiyalji sendromunda (FMS) Sistemik İmmün-İnflamasyon İndeksi (SII) ile kan parametreleri arasındaki ilişki değerlendirilerek hastalık aktivitesinin belirlenmesi amaçlanmıştır. Çalışmaya Ocak 2021 ve Ocak 2022 tarihleri arasında Fizik Tedavi ve Rehabilitasyon Kliniğine başvuran 109 FMS hastası ve 82 sağlıklı kontrol dahil edilmiştir. Yaş, cinsiyet, C-reaktif protein (CRP), eritrosit sedimentasyon hızı (ESR), beyaz kan hücresi (WBC), hemoglobin (HGB), ortalama korpusküler hacim (MCV), ortalama korpusküler hemoglobin (MCH), ortalama korpusküler hemoglobin konsantrasyonu (MCHC), kırmızı hücre dağılımı (RDW), trombosit dağılım genişliği (PDW), ortalama trombosit hacmi (MPV), trombosit (PLT), trombosit kriteri (PCT), lenfosit (LYM), monosit (MONO), nötrofil (NEU) düzeyleri hastane bilgi sisteminden retrospektif olarak taranmıştır. Trombosit-lenfosit oranı (PLR), nötrofil-lenfosit oranı (NLR), monositlenfosit oranı (MLR) ve sistemik immün-inflamasyon indeksi (SII) hesaplanmıştır. CRP ve ESR düzeyleri FMS hastalarında sağlıklı kontrollere göre daha yüksekti ancak değer aralığının dışında değildi (p<0,001). PDW (p<0,001), HGB (p<0,001), MCV (p<0,001), MCH (p<0,001) ve MCHC (p=0,02) düzeyleri hastalarda sağlıklı gruba göre daha düşüktü. Hasta ve kontrol grupları arasında yaş, WBC, NEU, LYM, MONO, RDW, MPV, PLT, PCT, SII, PLR, NLR ve MLR değerleri açısından istatistiksel olarak anlamlı fark yoktu. FMS hastalarında WBC düzeyleri ile SSS değerleri arasında (r=0,2; p=0,005) ve lenfosit düzeyleri ile WPI değerleri arasında (r=0,2; p=0,01) anlamlı pozitif korelasyon bulunmuştur. Çalışma sonuçlarına göre, SII'nin FMS'de belirleyici bir rolü yoktur, ancak hastalığın tanıda yararlı olabilecek bazı inflamatuvar bileşenleri vardır ve daha ayrıntılı çalışmalara ihtiyaç vardır.